The Colombia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Colombia's pharmaceuticals and healthcare industry.
The Analysts View :
The Colombian healthcare sector's high growth forecast is driven by strong demographics, increased healthcare needs, longer life expectancy and improved access to health facilities.
Increased healthcare spending in the public (as governments increase the proportion of fiscal expenditure devoted to healthcare) and private (as economies grow and per-capita wealth increases) sectors, as well as a growing awareness of preventative healthcare and the increasing burden of non-communicable disease, will drive growth.
This, combined with historical underinvestment in the region, will provide significant opportunities to drug companies looking to invest in the sector.
Headline Expenditure Projections
Pharmaceuticals : COP6,525bn (US$3.44bn) in 2010 to COP7,057bn (US$3.85bn) in 2011; +8.2% growth in local currency terms and +11.9% in US dollar terms.
Our forecast has been revised up moderately from Q111 due to macroeconomic factors.
Healthcare : COP29,437bn (US$15.53bn) in 2010 to COP30,814bn (US$16.82bn) in 2011; 4.7% growth in local currency terms and 8.3% in US dollar terms.
Our forecast has been revised up moderately from Q111 due to macroeconomic factors.
Medical devices : COP1,667bn (US$880mn) in 2010 to COP1,860bn (US$1.02bn) in 2011; 11.5% growth in local currency terms and 15.4% in US dollar terms.
Our forecast has been revised up moderately from Q111 due to macroeconomic factors.
The Analysts View :
The Colombian healthcare sector's high growth forecast is driven by strong demographics, increased healthcare needs, longer life expectancy and improved access to health facilities.
Increased healthcare spending in the public (as governments increase the proportion of fiscal expenditure devoted to healthcare) and private (as economies grow and per-capita wealth increases) sectors, as well as a growing awareness of preventative healthcare and the increasing burden of non-communicable disease, will drive growth.
This, combined with historical underinvestment in the region, will provide significant opportunities to drug companies looking to invest in the sector.
Headline Expenditure Projections
Pharmaceuticals : COP6,525bn (US$3.44bn) in 2010 to COP7,057bn (US$3.85bn) in 2011; +8.2% growth in local currency terms and +11.9% in US dollar terms.
Our forecast has been revised up moderately from Q111 due to macroeconomic factors.
Healthcare : COP29,437bn (US$15.53bn) in 2010 to COP30,814bn (US$16.82bn) in 2011; 4.7% growth in local currency terms and 8.3% in US dollar terms.
Our forecast has been revised up moderately from Q111 due to macroeconomic factors.
Medical devices : COP1,667bn (US$880mn) in 2010 to COP1,860bn (US$1.02bn) in 2011; 11.5% growth in local currency terms and 15.4% in US dollar terms.
Our forecast has been revised up moderately from Q111 due to macroeconomic factors.
Companies Mentioned :
Tecnoquimicas
Lafrancol
Laboratorios Genfar SA
Laboratorios Brussi
GlaxoSmithKline (GSK)
Pfizer
Merck & Co
Sanofi-Aventis
Novartis
Posts
No comments:
Post a Comment
Thanks for your visit, hope you enjoy the content, we expect to see you again soon.